RheinCell Therapeutics


We specialise in GMP-compliant manufacturing of human induced pluripotent stem cells (iPSCs) as fully characterized starting materials for “off the shelf” regenerative therapies. One of our core products is a library of HLA-homozygous iPSC lines from rigorously selected, patient-consented cord blood units. Each cell line matches potentially thousands to millions of recipients and permits allogeneic cell therapies through significantly reduced immunogenicity.

With state-of-the-art cell culture and processing capabilities, we also offer services along the complete iPSC workflow. Our iPSC experts develop protocols for cell differentiation, rigorously characterise and release-test cell lines, and establish cell banks in our high-security storage facilities.